Standardized CGM metrics for clinical care
| 1. Number of days CGM device is worn (recommend 14 days) | |
| 2. Percentage of time CGM device is active (recommend 70% of data from 14 days) | |
| 3. Mean glucose | |
| 4. Glucose management indicator | |
| 5. Glycemic variability (%CV) target ≤36%* | |
| 6. TAR: % of readings and time >250 mg/dL (>13.9 mmol/L) | Level 2 hyperglycemia |
| 7. TAR: % of readings and time 181–250 mg/dL (10.1–13.9 mmol/L) | Level 1 hyperglycemia |
| 8. TIR: % of readings and time 70–180 mg/dL (3.9–10.0 mmol/L) | In range |
| 9. TBR: % of readings and time 54–69 mg/dL (3.0–3.8 mmol/L) | Level 1 hypoglycemia |
| 10. TBR: % of readings and time <54 mg/dL (<3.0 mmol/L) | Level 2 hypoglycemia |
| 1. Number of days CGM device is worn (recommend 14 days) | |
| 2. Percentage of time CGM device is active (recommend 70% of data from 14 days) | |
| 3. Mean glucose | |
| 4. Glucose management indicator | |
| 5. Glycemic variability (%CV) target ≤36%* | |
| 6. TAR: % of readings and time >250 mg/dL (>13.9 mmol/L) | Level 2 hyperglycemia |
| 7. TAR: % of readings and time 181–250 mg/dL (10.1–13.9 mmol/L) | Level 1 hyperglycemia |
| 8. TIR: % of readings and time 70–180 mg/dL (3.9–10.0 mmol/L) | In range |
| 9. TBR: % of readings and time 54–69 mg/dL (3.0–3.8 mmol/L) | Level 1 hypoglycemia |
| 10. TBR: % of readings and time <54 mg/dL (<3.0 mmol/L) | Level 2 hypoglycemia |
CGM, continuous glucose monitoring; CV, coefficient of variation; TAR, time above range; TBR, time below range; TIR, time in range.
Some studies suggest that lower %CV targets (<33%) provide additional protection against hypoglycemia for those receiving insulin or sulfonylureas. Adapted from Battelino et al. (26).